Drugs /

dfp-10917

Back to Drugs List

Overview

NCI Definition [1]:
A deoxycytosine analog with potential antineoplastic activity. Upon administration, DFP-10917 is phosphorylated to generate its nucleotide form that functions as a deoxycytosine mimic and is incorporated into DNA in tumor cells. This causes DNA strand breaks during polymerization due to beta-elimination during the fidelity checkpoint, which results in G2/M phase-arrest and tumor cell apoptosis.

Clinical Trials

View Clinical Trials for dfp-10917

Dfp-10917 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating dfp-10917, 1 is phase 1/phase 2 (0 open) and 1 is phase 3 (1 open).

PML-RARA Fusion, t(15;17)(q22;q12), and t(15;17)(q24;q21) are the most frequent biomarker inclusion criteria for dfp-10917 clinical trials.

Acute myeloid leukemia is the most common disease being investigated in dfp-10917 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Dfp-10917
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Dfp-10917
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dfp-10917 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cndac, 2'-cyano-2'deoxy-1-beta-d-arabinofuranosylcytosine, nucleoside analog dfp-10917, 2'-cyano-2'-deoxyarabinofuranosylcytosine, 2'-c-cyano-2'-deoxy-1-beta-d-arabino-pentofuranosylcytosine
NCIT ID [1]:
C116744

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.